Pathology: la/mBC - HER2 positive - 1st Line (L1);
| la/mBC - HER2 positive - 1st Line (L1) | ||||
| PERTAIN, 2018 | CLEOPATRA, 2012 | PUFFIN, 2020 | ||
| pertuzumab plus trastuzumab plus docetaxel | 2 | T1 | T1 | |
| pertuzumab plus trastuzumab | 1 | T1 | ||
| trastuzumab | 0 | T0 | ||
| trastuzumab plus docetaxel | 0 | T0 | T0 | |